Explore

Trendline Trendline
CREATE Medicines Secures $122 Million to Advance In Vivo CAR T Programs for Autoimmune Diseases and Cancer

CREATE Medicines Secures $122 Million to Advance In Vivo CAR T Programs for Autoimmune Diseases and Cancer

CREATE Medicines Secures $122 Million to Advance In Vivo CAR T Programs for Autoimmune Diseases and Cancer
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges

BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges

BrainStorm Cell Therapeutics Prepares for Phase 3 ALS Study Amid Financial Challenges
Trendline Trendline
Autoimmunity BioSolutions Secures $1M Seed Extension to Advance Autoimmune Therapy

Autoimmunity BioSolutions Secures $1M Seed Extension to Advance Autoimmune Therapy

Autoimmunity BioSolutions Secures $1M Seed Extension to Advance Autoimmune Therapy
Trendline Trendline
Autoimmunity BioSolutions Secures Additional Funding to Advance Autoimmune Therapy

Autoimmunity BioSolutions Secures Additional Funding to Advance Autoimmune Therapy

Autoimmunity BioSolutions Secures Additional Funding to Advance Autoimmune Therapy
Trendline Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Trendline Trendline
PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability
Trendline Trendline
Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Platform in Immunology
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million
Trendline Trendline
Perspective Therapeutics Advances VMT-α-NET with High Response Rates and Manufacturing Expansion

Perspective Therapeutics Advances VMT-α-NET with High Response Rates and Manufacturing Expansion

Perspective Therapeutics Advances VMT-α-NET with High Response Rates and Manufacturing Expansion